Skip to content

Vor Biopharma VOR Debt-to-assets

Debt-to-assets at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.3×0.0×
Amgen logo
AmgenAMGN
0.6×0.0×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
0.1×0.0×
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
0.0×
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
0.0×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
0.0×

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,594%
Enterprise value$617.68M+5,866%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Calculated from Vor Biopharma’s reported figures.

Based on the most recent quarter.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's debt-to-assets?
Vor Biopharma (VOR) reported debt-to-assets of 0× in Q1 2026.
How has Vor Biopharma's debt-to-assets changed year-over-year?
Vor Biopharma's debt-to-assets decreased by 97.9% year-over-year, from 0.3× to 0×.
What is the long-term trend for Vor Biopharma's debt-to-assets?
Over 5 years (2020 to 2025), Vor Biopharma's debt-to-assets has grown at a -51.5% compound annual growth rate (CAGR), from 0.2× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.